ClinicalTrials.gg
CompletedNCT02244294Updated Sep 19, 2014

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

A Phase 2 interventional study of FLOMAX® capsules and Placebo capsules in Prostate Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
22nd of 48
176 · median 118
Started
2001
the only one that year
Phase 2
3 of 48
none open now
Registered
19th of 48
by date
Lead sponsor
5 of 48
Boehringer Ingelheim

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 22nd largest by enrollment, is the only one that started in 2001, is one of 3 in phase 2, and was the 19th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of six months of active treatment

03

Conditions studied

  • Prostate Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase I

  • Adult men, 45 years of age or older, diagnosed with acute urinary retention due to BPH
  • Patients who have never taken alpha-blockers or discontinued taking alpha-blockers 72 hours or more prior to entrance into this study
  • Patients that have been treated with an indwelling urethral catheter as treatment for acute urinary retention (AUR) due to BPH
  • Patients must be judged by the investigator to be reliable and willing to comply with all tests and examinations stipulated in the protocol
  • All patients must be willing to give meaningful, written, prior to participation in the trial, in accordance with regulatory requirements. Patients must also have sufficient understanding to communicate effectively with the investigator

Phase II - Patients who voided spontaneously, at least 100 mL and a post-void residual volume of ≤ 300 mL, at Visit 2

Exclusion criteria

Exclusion Criteria:

Phase I

  • Patients diagnosed with a symptomatic/active urinary tract infection (UTI) or an abnormal urine culture at baseline or 2 or more UTIs within the last six months. An abnormal urine culture was defined as:

    • A bacterial colony count of greater than or equal to 100,000 CFU/mL or
    • A bacterial colony count of greater than or equal to 100 CFU/mL of a known urinary pathogen in a symptomatic patient
  • Patients that have a distended bladder volume greater than 1.5 liters (1500 ml) of retention as measured by initial catheter urine volume
  • Patients with history of sexually transmitted disease within last two years
  • Patients with active genital herpes disease whose urinary function was impacted due to the disease
  • Patients who have a history of mechanical outlet obstruction excluding BPH (i.e., bladder neck contracture or stricture, bladder tumor, or bladder calculi)
  • Patients with urethral stricture disease
  • Patients with a history of bladder, prostate, or urethral surgery in the last three months
  • Patients presenting with AUR who were not been seen within 5 days of urethral catheter placement
  • Patients presenting with any of the following: active urinary stone disease, previous pelvic radiotherapy, perirectal inflammatory disorders or inflammatory bowel disease
  • Participation in another drug study within 30 days of Visit 1
  • conditions which may interfere with the patient's ability to participate in the study including, but not limited to, the following: neurologic, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, hematologic or respiratory disease and clinically relevant laboratory abnormalities not mentioned above (e.g., hematuria) based upon the clinical judgment of the investigator
  • Patients receiving cimetidine, ranitidine or warfarin within two weeks of study start date and who would potentially use such medications during the course of the trial
  • Patients currently treated with finasteride (PROSCAR®) and who would not discontinue its use upon entrance into the study
  • Patients with known to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
  • Patients with a history of myocardial infarction within six months of baseline
  • Patients with uncontrolled hypertension (systolic > 160 mmHg, diastolic > 100 mmHg) and patients with severe hypotension (systolic \< 90 mmHg)
  • Patients who have been using the following drugs, 72 hours prior to study start date, or who are unable to discontinue these drugs over the course of the study:

    • Alpha-adrenergic medication
    • Drugs with systemic anticholinergic activity including antihistamines. The following antihistamines are allowed: ALLEGRA®, CLARITIN® or ZYRTEX®
    • Antispasmodics or muscle relaxants
    • Parasympathomimetics, cholinomimetics or similar drug
  • Patients that have poorly controlled diabetes mellitus who suffer from peripheral neuropathy or diabetic cystopathy
  • Patients who suffer from neurological diseases affecting the bladder (i.e., multiple sclerosis, Parkinson's disease, stroke, and any bladder trauma that may be an exclusion criterion in the opinion of the investigator
  • Patients with a neurological impairment or psychiatric disorder that prevents their comprehension of the and/or the ability to comply with the protocol
  • Patients with a urine volume at the initial catheterization less than 300 mL
  • Patients with a diagnosis of active cancer, except basal cell carcinoma, within 5 years or less
  • Patients who had a transurethral resection of the prostate (TURP) within 5 years or less of study enrollment and irreversible urethral damage due to the procedure

Phase II

  • Patients with clinically, significant abnormal lab results including any baseline laboratory serum test with the following values:
  • \< 11.0 g/dL
  • Leukocytes \< 3,000 per mm3
  • Liver enzymes [ (SGOT), alanine transaminase (SGPT) and alkaline phosphatase]: more than two times the at baseline
  • Serum creatinine more than two times the upper limit of normal at Visit 1
  • Patients with clot retention, persistent gross hematuria (Visit 3 only), prostatitis, a symptomatic/active urinary tract infection (UTI) or an abnormal baseline urine culture
  • An abnormal urine culture was defined as:
  • A bacterial colony count of greater than or equal to 100,000 colony forming units (CFU)/mL or
  • A bacterial colony count of greater than or equal to 100 CFU/mL of a kown urinary pathogen in a symptomatic patient
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
176 participants (actual)

Study arms

  • Experimental
    FLOMAX®

    Drug: FLOMAX® capsules

  • Placebo comparator
    Placebo

    Drug: Placebo capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Successful spontaneous voiding after urethral catheter removal

    For Phase I of the trial

    Time frame: Up to 96 hours after start of treatment

  2. Maintenance of successful spontaneous voiding

    For Phase II of the trial

    Time frame: Up to 6 months after start of treatment

Secondary outcomes

  1. Change in voided urine volume

    Time frame: Up to 6 months after start of treatment

  2. Determination of post-void residual urine volume

    by ultrasound or bladder scan

    Time frame: Up to 6 months after start of treatment

  3. Time to recurrence of AUR

    For phase II of the trial

    Time frame: Up to 6 months after start of treatment

  4. Clinically significant changes from baseline in vital signs

    Time frame: Pre-dose, up to 6 months after start of treatment

  5. Number of patients with adverse events

    Time frame: Up to 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
Mar 2001
Primary completionActual
Jun 2005
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244294
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Mar 2001
Primary completion
Jun 2005
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion